IP Library Granted Patent US 9,303,258
Granted Patent B2
US 9,303,258 · App. 14/007,823 · Granted Apr 5, 2016

Method and compositions comprising small RNA agonist and antagonists to modulate inflammation

Inventors: Richard L. Gallo (San Diego, CA); Jamie Bernard (Westfield, NJ)
Assignee: The Regents of the University of California
C12N15/113A61K31/7105C12N15/117C12N2310/17C12N2330/00C12N2330/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,303,258
App. No.
14/007,823
Granted
Apr 5, 2016
Kind
B2
Abstract

The disclosure provides methods and compositions for modulating inflammation.

Claims (13)

1. A composition comprising a nucleotide sequence selected from the group consisting of:

(i) loop “a” of U1 snRNA consisting of GGGAGAACCAUGAUCACGAAGGUGGUUUUCCC (SEQ ID NO:2);

(ii) loop “b” of U1 snRNA consisting of GGGCGAGGCUUAUCCAUUGCACUCCGGAUGUGCUGACCCC (SEQ ID NO:3);

(iii) a fragment of a loop “c” of U1 snRNA consisting of 10-26 nucleotides of CGAUUUCCCCAAAUGUGGGAAACUCG (SEQ ID NO:4);

(iv) any of the foregoing sequences wherein U is T;

(v) complements of any of the foregoing sequences;

(vi) any of the foregoing sequences comprising a non-natural nucleotide; and

(vii) an oligonucleotide having 99% identity with any of the foregoing sequences wherein the oligonucleotide can stimulate IL-6 and/or TNF α production in a mammalian cell,

wherein the nucleotide sequence is chemically linked to a charge neutralizing agent and wherein the composition comprises a pharmaceutically acceptable carrier.

2. A method of inducing inflammation comprising contacting a tissue with a composition of claim 1 , wherein the composition induces TNF-alpha and/or IL-6 production.

3. A method of treating an infection in a subject comprising contacting a tissue with a composition of claim 1 , wherein the composition induces TNF-alpha and/or IL-6 production.

4. The method of claim 3 , wherein the infection is a skin infection.

5. A method of treating a skin wound comprising contacting a tissue with a composition of claim 1 , wherein the composition induces TNF-alpha and/or IL-6 production.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2018
From: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, OFFICE OF THE GENERAL COUNSEL
Reel/Frame 046798/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2015
From: GALLO, RICHARD; BERNARD, JAMIE
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 036313/0663 →
CONFIRMATORY LICENSE Recorded Dec 13, 2013
From: UNIVERSITY OF CALIFORNIA SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 031814/0969 →
Continuity (2)
Provisional Application 61472136 · Apr 5, 2011
Related Publication 20140031413A1 · Jan 30, 2014